7OM5

Anti-EGFR nanobody EgB4

Summary for 7OM5

• Entry DOI: 10.2210/pdb7om5/pdb
• Descriptor: Nanobody EgB4, GLYCEROL, ZINC ION, ... (4 entities in total)
• Functional Keywords: egfr, nanobody, cancer, signaling, immune system
• Biological source: Lama glama
• Total number of polymer chains: 2
• Total formula weight: 28613.82

Authors

Zeronian, M.R.,Janssen, B.J.C. (deposition date: 2021-05-21, release date: 2022-03-02, Last modification date: 2024-11-20)

Primary citation

Zeronian, M.R.,Doulkeridou, S.,van Bergen En Henegouwen, P.M.P.,Janssen, B.J.C.
Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.
Bmc Mol Cell Biol, 23:12-12, 2022

PubMed Abstract: The epidermal growth factor receptor (EGFR) is involved in various developmental processes, and alterations of its extracellular segment are associated with several types of cancers, in particular glioblastoma multiforme (GBM). The EGFR extracellular region is therefore a primary target for therapeutic agents, such as monoclonal antibodies and variable domains of heavy chain antibodies (VHH), also called nanobodies. Nanobodies have been previously shown to bind to EGFR, and to inhibit ligand-mediated EGFR activation.

PubMed: 35232398
DOI: 10.1186/s12860-022-00412-x

Experimental method

X-RAY DIFFRACTION (1.48 Å)